Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 04, 2024, titled "Sentynl Therapeutics announces global acquisition of Zokinvy�� (Lonafarnib) for treatment of Hutchinson-Gilford Progeria Syndrome from Eiger Biopharmaceuticals".
Press Release May 04 2024
Filed with NSE · · 5 pages · English
Summary by 6ix AI
This acquisition is aimed at enhancing Zydus's portfolio for treating rare diseases, specifically Hutchinson-Gilford Progeria Syndrome. The press release details the significance of Zokinvy as the first FDA-approved treatment for this ultra-rare genetic condition. The acquisition was finalized following a court-approved sale process, with Sentynl Therapeutics, a subsidiary of Zydus, acquiring global rights to Zokinvy.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Apr 26 2024
- Press Release Apr 23 2024
- Press Release Apr 22 2024
- Press Release Apr 20 2024
- Press Release Apr 01 2024
Later from Zydus Lifesciences
- Press Release May 09 2024
- Press Release May 11 2024
- Zydus Lifesciences Limited Press Release May 17 2024
- Press Release May 22 2024
- Press Release May 24 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences